 This study is being conducted to evaluate the safety profile and the Maximum Tolerated Dose MTD of TAK-901 in adult patients with advanced solid tumors or lymphoma. This study will help to identify the recommended phase 2 dose and infusion duration, and describe the pharmacokinetics of TAK-901. 